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Contents of Amendments 
 
We thank the reviewers for his/her time in reading and commenting on the thesis. Below 
are the contents of clarifications and amendments made to the thesis in light of the 
comments. 
 
1. Reviewer 1 
2. Reviewer 2 
3. Amended manuscript – Implications of variability in the distribution of 
chemoresponse genotypes between Asians and Caucasians in colorectal cancer 
4. Amended manuscript – Meta-analysis of clinical outcomes from 
fluoropyrimidine chemotherapy in Asians and Caucasians 
 
Differences between Asians and Caucasians in chemotherapeutic related outcomes 
in patients with colorectal cancer 
REVIEWER 1 - (comments in bold and italics are made by candidate) 
 
General comments 
This thesis comprises two parts. The first is a review of the literature on genetic 
polymorphisms linked with toxicity and response to chemotherapeutic agents commonly 
used in colorectal cancer, with a focus on differences between Caucasian and Asian 
populations. The second is a meta-analysis of phase II studies involving 
fluoropyrimidines among colorectal cancer patients, the outcome of interest being 
occurrence of three defined side-effects and response/survival rates. The primary 
hypothesis is that racial differences that have been observed in the literature can be 
predicted by prevalence of genetic variants which predispose to these outcomes. 
 
I would suggest that the literature review should not be limited in scope to the genetic 
factors, because this reduces its usefulness as an adequate basis for the meta-analysis 
which forms the substantive component of this thesis. Specifically, if it is widely 
accepted (‘dogma’ is the term used on page 63) that response and survival are more 
dependent on tumour features than host genetic makeup, than an understanding of the 
role of non-genetic determinants is critical for the proper appreciation of the field. These 
points are alluded to in the brief discussion on page 27-28, but deserve more attention. 
 
As was pointed out in the discussion pages of “Implications of variability in the 
distribution of chemoresponse genotypes between Asians and Caucasians in colorectal 
cancer”, non-genetic factors were considered. In fact, we have duly noted that “... such 
differences may be prevalent outside of genetics as well.” (pg 39,  para 1, line 4). We 
did not expand on these points for we felt it may distract the readers from the main 
points that we were trying to convey; which were that variability in the distribution of 
chemoresponse genotypes between Asians and Caucasians in colorectal cancer may 
result in different outcome. We believed it would make sense to investigate genetic first 
before phenotypic (somatic mutation and non-inherited) variability, as phenotypic 
variability has more confounders. When we considered phenotypic variability we 
realized it would be quite considerable, and better discussed in a future additional 
composition 
 
A second general comment relates to the conduct of the meta-analysis. This may indeed 
be an appropriate tool to answer this research question. However, it is important that the 
candidate demonstrates a thorough understanding of the uses and limitations of this 
design. There should be an attempt to search out and grasp the issues involved in 
conducting the primary studies, beyond the numerical results, because these issues 
influence the interpretation of the findings in the meta-analysis. The present study lacks 
depth, and critical portion of the analysis are missing (see below). 
 
I thank the reviewer for his/her comments which were very useful. We appreciate that 
the reviewer agrees that the tool which we have chosen was the appropriate one as well. 
In the light of the comments made above, several amendments and added data were 
incorporated. Please read these in the “Specific comments” section. 
 
In summary, I would suggest that this is a promising piece of work, but the scope and 




A large number of studies were identified from the publication literature. At certain 
points, however, the referencing appears to be incomplete. These include the studies 
given in the tables (e.g. Table 6, the first 2 studies cited are not in the reference list), 
some figures (figures 2 and 3 are not referenced), and portions of the text (e.g. page 14, 
para 2 and 3). Of the five articles cited in the discussion (page 27-8), only one (Iacopetta 
2002) is found in the list of references (in which it is listed as a 2001 article).  
 
I apologize for the incomplete referencing. Amendments have been made to correct 
these. These include the addition of the two studies listed in Table 6 (Lin WY et al, 
Toffoli G et al, etc), portions of text on (new) pg 25 (Soong R et al) and other citations. 
Other citations that were left out previously but have since been included are: Rossit 
AR et al (2002), Marsh S et al (1999) etc. 
 
On the whole, the discussion is rather brief, and the last 2 paragraphs appears to be 
related to specific agents rather than serving to summarize and conclude the section. 
I thank the reviewer of his/her comments. Accordingly a summary section has been 
added at the end of the discussion:  
“In summary, we have identified a large number of published literature which shows 
the association (even causal pathways) between genetic polymorphisms with toxicity 
and response to chemotherapeutic agents commonly used in CRC, with the primary 
focus on differences between Asian and Caucasian populations. Perhaps it will not be 
too far off before personalized medicine becomes a reality, bringing with it better 
treatment outcomes.” (pg 41, para 1) 
Part II  
The candidate has made a good attempt to bring together the findings of many studies, 
and has chosen an appropriate tool. 
For a meta-analysis to be of publishable quality, it should include a detailed description 
of the exact search terms and a flow chart showing, in a step-wise fashion, how studies 
were selected for inclusion. The key definitions (e.g. definitions of ‘response’ used in the 
various studies, and any variations between studies) should be made clear. 
 
As suggested, a flow-chart (new figure 1) showing, in step-wise, fashion how studies  
 
were selected for inclusion was shown. Exact search terms were also shown. Key  
 
definitions were discussed in the ‘Materials and Methods’ section: 
 
“The common toxicity criteria (CTC) differs somewhat between the WHO, ECOG and 
NCI grading scale. Even within the NCI grading system, there are different versions 
depending on the publication date of the descriptive terminology that can be utilized for 
Adverse Events (AE). For our meta-analysis, we have decided to term all Grade 3 
toxicity and above as severe AE. Hence depending on the different criteria (CTC) being 
used, there may be slight nuances. For example, comparing diarrhea, severe toxicity 
(grade 3 and above) may include NCI (CTC ver 3) which includes  >7 loose stools/day 
and death (grade5), NCI (CTC ver 1) which includes 7-9 loose stools/day, and WHO >7 
loose stools/day (no death). It was unfortunate we were not able to obtain the raw data 
to stratify the analysis accordingly. 
 
In general, the key definitions of response used in the various studies were similar 
between the various studies. Completed response (CR) was defined as disappearance of 
all objective evidence of disease lasting for more than 4 weeks. Partial response (PR) 
was defined as a decrease of 50% or greater than 50% in the measurable lesion lasting 
for more than 4 week. Progressive disease (PD) was defined was defined as an increase 
of 25% or greater than 25% in the measurable lesion lasting for more than 4 week. All 
other patients are considered to have stable disease”. (pg 87 para 2-3). 
 
The funnel plot is also essential. In this case, it is mentioned in the methods but not 
included in the results. 
 
A funnel plot has now been drawn in the results section (new figure 2). 
 
 
The Forest Plots (figures 1-4) are incomplete. The point estimates and confidence 
intervals for the Asian studies are missing in all figures. 
 
Printing issue – now addressed. The new forest plots can be seen in figure 3-7 
 There is no attempt to examine the sources of heterogeneity. The latter is a statistical 
concept – while the reasons behind this are important in interpreting the results of the 
meta-analysis. Without an understanding of why the studies could be heterogeneous, it is 
not possible to state how meaningful the final summary estimates is and whether there is 
a need to further stratify the studies (e.g. by patient or tumour characteristics). 
Among the limitations mentioned in the discussion: two points stand out:                   
(1) The criteria for toxicity are not standardized between studies and  
(2) Phase II trials had to be used because of the lack of phase III trials in Asian 
populations, although the latter would have been more appropriate 
While it is commendable that these limitations are recognised, it is not sufficient 
to state them in passing. There should be an effort to examine what impact these 
limitations have on the study and what steps can be taken to interpret the results in 
the most valid way possible, given the constraints. E.g. by stratifying the analysis, 
or using sensitivity analysis. 
 
I thank the reviewer for his/her advice. Accordingly, a discussion of the sources of 
heterogeneity was included in the ‘Discussion’ section. This can be seen in pg 94, para 
2 and  pg 97, para 3-5 
 
Pg 94, para 2 – “In this paper, it is possible that sources of heterogeneity may have 
been introduced by characteristic of the design and conduct of the studies. Even then, it 
may often be difficult to explain heterogeneity. For example, (Owen et al., 2003) 
carried out a review of the effect of breast feeding in infancy on blood pressure in later 
life. Although there was clear heterogeneity, the authors were unable to explain it. The 
obvious candidate explanatory variable, the age at which the blood pressure was 
measured, was unable to explain the heterogeneity. Under these circumstances, the 
authors accept the existence of the heterogeneity and say that the greater uncertainty 
that this adds to their estimate should be reflected in the method of estimation and 
calculation of the confidence interval. For our study, we did this using a random 
effects model, where we regard each study as estimating a different effect.” 
 
Pg 97, para 3-5 - “Significant analysis was also spent on heterogeneity. Our approach 
to understanding heterogeneity in our data is to include a wide range of studies, but 
then examine the sensitivity of the results by looking at more narrowly drawn subsets 
of the studies.  
 
Different data sets resulted in different nuances. For example, Yeh et al defined  CR as 
disappearance of all objective evidence of disease, including all necessary imaging 
studies, lasting for more than 4 weeks. On the other hand, Cure et al defined CR as 
disappearance of all signs and symptoms lasting for more than 9 weeks. The grading of 
toxicity is also potentially skewed, coming from reports using a mixture of WHO and 
NCI toxicity criteria. Such differences may also result in a source of heterogeneity in 
the results. 
 
In meta-analysis, when the differences in results between studies is greater than would 
be expected by chance, we may need to investigate whether the observed variation in Comment [RS1]: according to who? 
results across studies is associated with clinical and/or methodological differences 
between studies. In fact, an uncritical use of the technique can be very misleading. Hence, 
exploring the possible reasons for heterogeneity between studies is an important aspect 
in conducting a meta-analysis.” 
   
Also in the ‘Discussion’ section, a thorough discourse on the limitations on our study 
was done. These were an emphasis on how sensitivity analysis can further strengthen 
our analysis, although it should be said that we have actually performed some form of 
sensitivity analysis using our original analysis (i.e. by stratification). This can be seen 
in pg 98, para 2-3:  
“It is widely accepted that the robustness of a meta-analysis be examined in a thorough 
sensitivity analysis. In many ways, we conducted our sensitivity analysis by calculating 
the overall effect size in toxicity, response and survival. We then stratified this effect 
size into ‘Asian’ and ‘Caucasian’ groups. Other more conventional methods that could 
have been performed include applying the meta-analytic approach to subsets of the K 
studies, and/or applying the leave-one-out method. Other than invoke the leave-one-out 
method, other methods may also include a sensitivity analysis by applying the meta-
analysis to subsets of studies based on high-quality versus low-quality studies. 
 
We did not conduct any further subgroup analysis since the primary study was an 
assessment between Asians and Caucasians.” 
Differences between Asians and Caucasians in chemotherapeutic related outcomes 
in patients with colorectal cancer 
REVIEWER 2 - (comments in bold and italics are made by candidate) 
 
This is a literature review of interethnic variability between Asian patients and Caucasian 
patients in association with chemotherapy treatment, and exploration of possible genetic 
variants that could explain these interethnic differences. The thesis is written up in 2 
sections, the first dealing with the genotype of candidate genes that was associated with 
chemotherapy for colorectal cancer. The second part goes into actual details on the 
differences in pharmacodynamics of chemotherapy for colorectal cancer between the 
Asian and the Caucasian populations. In general, the language is good, and easy to 
understand. 
Comments: 
1. In the introduction, these should be discussion on why genotype was discussed 
first, followed by phenotypes because obviously more logically the phenotype 
could be discussed first, followed by an explanation on the basis of genotype. 
 
I agree with the reviewer that it would make for better logic if phenotype was 
explained, followed by genotype. However, as was pointed out in the discussion 
pages of “Implications of variability in the distribution of chemoresponse 
genotypes between Asians and Caucasians in colorectal cancer”, non-genetic 
factors were considered. In fact, we have duly noted that “... such differences 
may be prevalent outside of genetics as well.” (pg 39, 1 para, line 4). We did not 
expand on these points for we felt it may distract the readers from the main 
points that we were trying to convey; which were that variability in the 
distribution of chemoresponse genotypes between Asians and Caucasians in 
colorectal cancer may result in different outcome. We believed it would make 
sense to investigate genetic first before phenotypic (somatic mutation and non-
inherited) variability, as phenotypic variability has more confounders. When we 
considered phenotypic variability we realized it would be quite considerable, 
and better discussed in a future additional composition 
 
2. Given ethnicity is the main focus of the review, it would definitely help to 
define the populations that are being studied. How homogenous are the 
populations, ie when we speak of Asians, it could range from Southern China, 
Japan, to Northern India, which encompasses a large population of 
heterogeneous ethnogeography. 
 
For this thesis, ethnicity was defined by geography. We have now added 
clarifying text in the methods on what countries were considered (see Table 1 – 
pg 110 and pg 86, para 1). Our data supports this grouping which shows that 
Asians tend to have a more homogeneous toxicity profile and hence the 







3. In the analysis of genetic variants that can affect irinotecan metabolism, it is 
worth mentioning that there is interethnic variability in the bilirubin levels, and 
that UGT1A1*6 polymorphism is the main polymorphism in Chinese and 
Japanese. 
 
I thank the reviewer for highlighting an important aspect of this review. Added 
material in the Irinotecan section have been added to address the reviewer’s 
concern. This is shown on pg 33 para 1:  
“In patients homozygous for UGT1A1*6 (compared with the reference group), it 
has been reported that the mean absolute neutrophil count was 85% lower and 
the prevalence of grade 4 neutropenia was 27% (Jada SR et al 2007). 
Furthermore, the presence of the UGT1A1*6 allele was associated with an 
approximately 3-fold increased risk of developing severe grade 4 neutropenia 
compared with the reference genotype group. These exploratory findings suggest 
that homozygosity for UGT1A1*6 allele may be associated with altered SN-38 
disposition and may increase the risk of severe neutropenia in Asian cancer 
patients, particularly in the Chinese cancer patients who comprised 80% (n = 36) 
of the patient population in their study.” 
 
4. In the second analysis, it should be noted in there are non-genetic reasons for 
interethnic variability of drug response and some of these reasons could be 
mentioned. For example, the administration of 5-fluorouracil may not have 
been standardized across all studies, and with differing durations of infusion, 
this may affect the effects of 5FU as it is a schedule dependent drug. 
 
In the second analysis, the lack of discussion for any non-genetic reasons for 
interethnic variability was an intended one so as not to distract the reader from 
the main crux of the matter (please see point 1 above). However a similar 
discussion was actually done on our earlier review, “Implications of variability in 
the distribution of chemoresponse genotypes between Asians and Caucasians in 
colorectal cancer”. 
 
In our second analysis, the lack of any standardized administration of 5-
fluorouracil was also noted as part of our limitations of the study. Please see 
below (pg 96, para 3). 
 
 
5. How were the data collected for toxicity? Were these similarly collected across 
studies, using the same toxicity criteria? How does the test of heterogeneity 
account for these differences in reporting across studies? 
 
A more thorough discussion of the method for the meta-analysis has been 
prepared in ‘Materials and Methods’.  
“It is important to note that this study has many limitations. To obtain enough 
series and sample numbers for analysis, we considered all types of FPs 
administered in various doses, schedules and with various modulators (such as 
leucovorin) in our analysis, even though all these factors are believed to 
influence the efficacy of FP treatment. Due to a lack of Phase III Asian trials, 
our data is based on Phase II data even though the goals of Phase III trials make 
their data more appropriate. Moreover, in such Phase II, not all the endpoints 
were reported on in many series, making for inconsistent endpoint comparisons. 
This is particularly pertinent to toxicity endpoints, which are only represented by 
three types in this study – diarrhea, nausea and/or vomiting and stomatitis. “ - 
(pg 96, para 3) 
 
 To our knowledge, toxicity was reported according to standard protocols 
obtained from the study design. 
 
 
6. What were the percentage of patients on 5FU, S-1, UFT, and Xeloda? 
 
Absolute numbers are displayed in Table 1. Percentage-wise, 5FU = 22/43  
 




7. How was ethnicity defined? Was it based on self-reporting? 
 
None of the primary studies described how ethnicity was determined, as it was  
 
not their goal.  As discussed in point 2 above, ethnicity was hence considered  
 
according to geography. Ethnicity was self-reported by authors of the respective  
 
studies. 
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ABSTRACT 
Introduction: Over the last few years, a number of DNA sequence variants have been 
identified as potential indicators of patient outcome from chemotherapeutic agents used 
currently in colorectal cancer (CRC) treatment. These have included variants such as 
DPYD*2A, TYMS(-100) 2R>3R, TYMS(-58) C>G, TYMS(+15705) ins>del, 
MTHFR+677 C>T and MTHFR+1298 A>C for fluoropyrimidines, UGT1A1*28 for 
irinotecan, and ERCC1+118 C>T, ERCC2+751 A>C, XRCC+399 G>A and GSTP1+105 
G>A for oxaliplatin. However, significant variability in the frequency and distribution of 
a number of these genotypes is known to exist between racial populations. Taken 
together, these findings would suggest that different racial populations are likely to 
experience different outcomes to respective chemotherapy agents.  
 
Aim: The aim of this study was to investigate the potential implications to Asians of 
variations in the frequency of genotypes related to CRC chemotherapy-related patient 
outcomes between Asians and Caucasians. 
 
Methods: Public databases were searched for (1) articles reporting on associations 
between genotypes and chemotherapy-related outcomes for agents used in CRC treatment 
and (2) the frequency of outcome-associated genotypes in healthy Asian and Caucasian 
populations. Chemotherapy-related outcomes for Asians were then inferred by 
identifying the outcome association of a given genotype and its relative frequency in 
Asian and Caucasian populations. 
Results: For fluoropyrimdines, a lower toxicity rate, shorter patient survival and a lack of 
survival benefit for Asians was inferred by their genotype frequencies in TYMS(-100) 
2R>3R, TYMS(-58) C>G and MTHFR+1298 A>C. No outcome differences were 
predicted by DPYD*2A, TYMS(+15705) ins>del, and MTHFR+677 C>T due to their 
similarity in frequency between the two populations. Reported frequency ranges of 50-
66% for Caucasians and 15-49% for Asians for the UGT1A1*28 related to irinotecan 
toxicity implied that Asians should experience less irinotecan toxicity. For oxaliplatin, 
relative frequencies of ERCC1+118 C>T and ERCC2+751 A>C for Asians implied 
worse survival, while those for XRCC+399 G>A and GSTP1+105 G>A suggested 
reduced resistance and better survival for Asians respectively. 
 
Conclusion: Marked differences in the frequencies of many CRC chemotherapy 
outcome-related genotypes exist between Asians and Caucasians. Based on some 
genotypes, Asians could be expected to experience lower toxicity and shorter survival 
times from fluoropyimidines, and lower toxicity from irinotecan. Both worse and 
improved outcome prospects from oxaliplatin-based chemotherapy are implied depending 
on the genotype examined. 
BACKGROUND 
In an age where personalization of medicine is increasingly improving treatment efficacy, 
it is relevant to consider its implications for drug administration to different racial 
populations. Pharmacogenetics has shown inter-individual drug handing can be 
influenced by subtle DNA variations in genes encoding proteins involved in the 
pharmacology of the agents (McLeod et al 1998). At the same time, the sequencing of the 
human genome and recent HapMap analysis has catalogued numerous differences in 
DNA sequence between races. Given the likelihood that sequence variability between 
races includes pharmacogenetically-relevant loci, it is reasonable to anticipate that 
personalized medicine (PM) would manifest itself as alternative treatment strategies 
being effective to different races as a whole. 
 
Taken together, these facts suggest a potentially feasible approach to anticipating which 
treatment strategies may be more effective to difference races as a whole could be to 
examine the relative frequencies of PM-related genotypes between racial populations. 
However, few studies have drawn together the patient outcome associations of PM-
related genotypes and their distribution in racial populations. 
 
In oncology, a good model for examining this approach is the administration of 
chemotherapeutic agents for colorectal cancer (CRC). For many CRC drugs, many 
genotypes have now been identified as potential modulators of patient response to the 
agents. Moreover, the distribution of many of these genotypes by race has also been 
characterized - albeit not as a specific goal - in many studies.  
 In this study, we review the evidence linking host genotypes to patient outcome from 
treatment with the many CRC agents currently in clinical practice, consolidate the data on 
the distribution of the genotypes in Caucasians and Asians and consider the implications. 
With modern agents primarily developed in the Western world and Eastern populations 
increasing rapidly, Caucasians and Asians are chosen as a relevant focus. 
METHODS 
Studies associating gene variants with patient outcome for agents used in colorectal 
cancer chemotherapy were identified by extensive review of PubMed records. Search 
terms included genotype, polymorphism, fluorouracil, capecitabine, tegafur, oxaliplatin, 
irinotecan, erbitux, C225, bevucizumab. The search identified 367 studies and the last 
search was performed on the 2nd August 2007. Countries that were identified included 
Frequencies of relevant genotypes were identified by a review of studies identified 
through PubMed searches using the following terms: genotype, polymorphism, 
dihydropyrimidine dehydrogenase, thymidylate synthase, methylene tetrahydrofolate 
reductase, UGT, carboxyesterase, ABC, ERCC, XRCC, GST. The search identified 367 
studies and was not restricted to studies on cancer. The last search was performed on the 
2nd August 2007. For both searches, additional studies were identified from references 
given in PubMed-identified studies. 
 
FLUOROPYRIMIDINES 
Background and mechanisms 
The fluorinated pyrimidine analogues, or fluoropyrimidines (FPs) are currently the most 
commonly used chemotherapy agents in CRC chemotherapy. The family of compounds 
includes 5-fluorouracil (5-FU), capecitabine, tegafur or UFT and S-1, with the most 
commonly used being the parent compound, 5-FU. 
 
As pyrimidine analogues, the FPs are considered to act by (1) incorporating into RNA 
leading to interference with transcriptional machinery and (2) incorporating into DNA, 
activating stress pathways. A third mechanism is the inhibition of thymidylate synthase 
(TS). The FP metabolite, flourodeoxyuridylate (FdUMP), binds TS in an irreversible 
ternary complex with the folate co-factor, methylene tetrahydrofolate (CH2FH4). TS is 
the sole enzyme for de novo synthesis of thymidylate in humans, hence its inhibition - 
disrupting nucleotide pools - is detrimental to the cell (Soong R et al, 2005).  
 
With conversion of FPs into its metabolites an important step in determining their 
cytotoxicity, the activity of their metabolizing enzymes become significant factors. The 
involvement of CH2FH4 in TS inhibition makes folate regulation a potentially important 
factor as well. It is no surprise therefore that the prominent gene variants in FP 
pharmacogenetics have been in genes encoding enzymes involved in drug clearance 
(dihydropyrimidine dehydrogenase), drug activity (thymidylate synthase) and folate 
regulation (methylene tetrahydrofolate reductase) (Soong R et al, 2005). 
Dihydropyrimidine dehydrogenase (DPD) 
DPD is the initial and major enzyme in the catabolism of 5-FU. As more than 80% of 5-
FU is metabolised by DPD, the activity of the enzyme greatly influences the efficacy and 
toxicity of 5-FU. Reduced DPD activity is associated reduced metabolism of 5-FU 
resulting in severe or fatal toxicities manifested by marked neutropenia, mucositis, 
neurological dysfunction and death (Diaso et al 1988, Milano et al 2006, Wei et al 1996). 
In cases of patients with unexpected severe 5-FU toxicity, reduced DPD activity in 
peripheral blood mononuclear cells was detected in 39-61% of cases (Van Kuilenberg et 
al 2004). 
 
In 1995, Meinsma et al. characterized a G>A variant in the splice donor site 
(IVS14+1G>A) of DPYD (the gene encoding DPD) resulting in loss of exon 14 (Van 
Kuilenberg et al 1997). The variant was linked to reduced DPD activity (Vreken et al. 
1996), providing the first paradigm of a pharmacogenetic basis to DPD deficiency. 
Screening for IVS14+1G>A gene variant (since classified as DPYD*2A) in patients with 
grade 3 or 4 5-FU toxicity has shown that 24-28% of these patients have this variant, 
markedly higher than its frequency of approximately 0-5% in the general population (Van 
Kuilenberg et al 1997), suggesting the variant could be a useful marker for predicting 
toxicity to FP treatment. More than 40 other gene variants of DPYD have since been 
reported, with about 17 directly associated with marked 5-FU toxicity (Van Kuilenberg et 
al ). However, their prevalence is rare and the predictive value has not been investigated. 
 
According to race, frequencies of DPYD*2A have been reported to range between 0-4% 
in Caucasians and 0-5% in Asians (Table S1). The low prevalence of the variant in the 
populations, together with the large variations in sample sizes make it difficult to gauge 
whether differences in frequency exist between the populations, and also the potential 
influence of DPYD*2A frequencies on inter-racial FP handling. 
Thymidylate synthase (TS) 
There are three prominent gene variants in the TYMS gene encoding TS. One is a tandem 
repeat polymorphism in the enhancer region (TSER) of TYMS, comprising 2 (2R) or 3 
repeats (3R) of a 28 base pair sequence, although up to 9 repeats have been observed. A 
second common varaint is a G>C single nucleotide polymorphism (SNP) within the 3R 
allele, and a third is 6 base pair deletion in 3’ untranslated region of TYMS (1494del6). 
 
The TSER polymorphism has been linked to TS levels, with the 3R encoding high TS 
amounts. With higher TS levels requiring higher FP levels for inhibition, it can be 
expected that the 3R variants would associate with poorer sensitivity to FPs. Indeed, 
several studies have reported an association between TSER polymorphism in tumor tissue 
with clinical outcome in patients with CRC treated with 5-FU. In a study of 221 CRC 
patients treated with 5-FU, an improvement in overall survival was seen in patients with 
at least one 2R allele (Iacopetta et al 2001). In a study of 166 CRC patients receiving 
adjuvant 5-FU, patients with 3R/3R genotype had longer disease free survival and overall 
survival (Hitre et al 2005). In patients with advanced CRC receiving 5-FU based therapy, 
the 2R/2R genotype was associated with a higher response rate and overall survival 
compared with the 3R/3R genotype (Marsh et al 1999). The median survival for patients 
with 2R/2R and 3R/3R genotypes was 16 months and 12 months respectively. In a study 
of neoadjuvant 5FU-radiotherapy, the likelihood of tumor downstaging was a reduced in 
rectal cancer patients with the 3R/3R genotype (Villafranca et al 2001). An association 
between germ line TSER genotype and toxicity in patients with CRC following 5-FU 
based chemotherapy has also been reported. Pullakart et al reported the grade 3 toxicity 
was 63% in patients with 2R/2R genotype (Pullakart et al 2001). In a study by Lecomte et 
al, the grade 3/4 toxicity rate of patients with the genotypes 2R/2R, 2R/3R and 3R/3R 
was 43%, 18% and 3% respectively (Lecomte et al 2004). 
 
The 3G genotype is associated with increased translational efficiency and higher TYMS 
expression (Mandola MV et al 2003). The combination of single nucleotide 
polymorphisms (SNP) and VNTR allows the combination of 3 TSER alleles: 2R, *3G 
and *3C. Marcuello et al (Marcuello et al 2004) then divided the genotype into two 
groups - high expression genotype: *2R/*3G; *3C/*3G; *3G/*3G; and low expression 
genotype: *2R/*2R; *2R/*3C; *3C/*3C. A higher overall response (OS) was observed in 
the group of patients with a low expression genotype. The median time to progression 
was 12 months and 9 months in the low and high expression groups, respectively. OS 
was significantly longer in the low expression group. In this group the median OS was 
not achieved at 50 months of follow-up in contrast to the 20 months observed in the high 
expression group. Kawakami et al also classified the genotypes into a high and low 
expression type (Kawakawi et al 1999). Patients who received oral FPs survived longer 
than the patients with no treatment in the group of low expression type. However, there 
was no benefit of oral FPs observed in the group of high expression genotype.  
 The 6 base pair deletion located in 3'-UTR of TYMS (1494del6) gives a destabilised 
mRNA structure and is associated with decreased TYMS expression (Ulrich et al 2000) 
and a reduced response to 5-FU (McLeod et al 2003).  
 
Significant inter-racial differences in the frequencies of the TSER variants exist. The 
range of frequencies of the 3R3R variant reported in Asians (64-86%) is markedly higher 
than that for Caucasians (22-38%). Given the reported clinical associations of the 3R3R 
variant, the frequencies suggest Asian could be expected to have lower toxicity rate, 
poorer response rates and a lack of survival benefit from FP treatment. Similar 
differences exist in the frequencies of the 3G variant. The frequency of “high expression” 
genotypes in Asians (64-86%) is much higher than that reported in US Caucasians (40%). 
Taken with the results of Kawakami et al. showing a lack of survival benefit for high 
expressors, the frequencies too project a lack of survival benefit from FP treatment for 
Asians. The distribution of the TS1494del6 genotype in Caucasians (45-49%) and Asians 
(46%) does not differ. 
Methylene tetrahydrofolate reductase (MTHFR) 
MTHFR catalyzes the conversion of CH2FH4 - a key co-factor in TS inhibition – to 
methyl-tetrahydrofolate, providing a basis for its levels to influence FP sensitivity (Figure 
1). Two common polymorphisms of MTHFR have been described: C677T and A1298C. 
The variant alleles for both loci are associated with reduced enzymatic activity (Frosst et 
al 1995, van der Put et al 1998). The reduced activity projects to increased CH2FH4 
availabilty, linking the variants to increased 5-FU sensitivity.  
 Indeed, associations between C677T and increased response have been reported (Cohen 
et al 2003, Jakobsen et al 2005, Etienne et al 2004), however such associations have not 
been observed in all studies (Marcuello et al 2006).  Counter-intuitively, A1298C variants 
have been associated with poorer survival in patients treated with fluorouracil-based 
treatment (Etienne et al 2004), although others report no association with response rate 
(Jakobsen et al 2005, Marcuello et al 2006).  
 
The frequencies of the C677T variants are well characterized, as they have also been 
considered potential cardiovascular-related factors. The large number of studies however, 
has provided a large range of frequencies for the same races, making for no observable 
differences in C677T frequencies between Caucasians (30-63%) and Asians (27-68%). 
The range of frequencies of A1298C is slightly higher in Asians (67-68%) than 
Caucasians (44-62%), implying poorer survival rates for Asians given the findings of 
Etienne et al. (2004). 
IRINOTECAN 
Background and mechanisms 
Irinotecan (CamptosarTM; Campto ®, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] 
carbonyloxycamptothecin, CPT-11) has become a valuable drug in the treatment of 
metastatic and irresectable colorectal cancer (Saltz et al. 2000; Vanhoefer et al. 2001; 
Douillard et al. 2003; Grothey et al. 2004). The agent is a prodrug. The active compound 
(7-ethyl-10-hydroxycamptothecin; SN-38) is a potent topoisomerase-1 inhibitor, which 
stabilizes the DNA-topoisomerase I complex by binding to it. This prevents the resealing 
of single strand breaks in double-stranded DNA (Hsiang et al 1989) and ultimately 
leading to cellular death. SN-38 is inactivated via biotransformation to SN-38 
glucuronide (SN-38G) via uridine diphosphate glucuronosyltransferase (UGTs) which are 
the same enzymes that conjugate bilirubin (Iyer et al 1998) (Figure 2). 
 
The elimination pathways of irinotecan are partly mediated by drug efflux pumps that 
belong to the superfamily of adenosine-triphosphate binding cassette (ABC) transporters. 
These transporters include MDR1 P-glycoprotein (ABCB1), MDR associated protein 1 
and 2 (ABCC1, ABCC2), and breast cancer resistance protein (ABCG2). 
 
UDP-glucuronosyl-transferases (UGTs) 
The UGT family mediates the glucuronidation of lipophilic xenobiotics and endogenous 
substrates such as bilirubin. Expression of a prominent isoform, UGT1A1 is highly 
variable with an inter-patient variability in the rate of SN-38 glucuronidation of up to 50 
fold (Iyer et al 1999). More than 50 genetic variations in the promoter and coding regions 
of the gene are known to decrease the enzyme activity (Kadakol et al 2000). 
 
The most prominent variant of UGT1A1 is UGT1A1*28, which is a 7 repeat variation of 
commonly 6 TA repeats in the promoter region that ranges between 5-8 repeats (Iyer et al 
2002). The UGT1A1*28 allele results in reduced UGT1A1 expression and therefore 
decreased SN-38 glucuronidation leading to increased levels of SN-38 and an increased 
risk of side effects (Iyer et al 1999, Iyer et al 2002, Ando et al 2002). In patients treated 
with irinotecan based chemotherapy, those heterozygote or homozygote for UGT1A1*28 
had an increased risk of severe diarrhoea and neutropenia (Iyer et al 2002, Ando et al 
2000). In patients with metastatic CRC receiving irinotecan based chemotherapy, the 
association between the UGT1A1*28 allele with grade 3-4 diarrhoea (Marcuello et al 
2004) and neutropenia (Innocenti et al 2005) has also been observed.  
 
Other variants of UGTs have been associated with irinotecan outcome. Carlini LE et al. 
(Carlini et al 2005) reported patients treated with capecitabine and CPT-11 with 
genotypes conferring low UGT1A7 activity (*2/*2 or *3/*3) and/or the UGT1A9-118 
genotype were more likely to exhibit greater anti-tumour response with little toxicity. 
UGT1A1-3165G>A has been reported to predict for risk of neutropenia (Innocenti et al. 
2005). 
 
In patients homozygous for UGT1A1*6 (compared with the reference group), it has been 
reported that the mean absolute neutrophil count was 85% lower and the prevalence of 
grade 4 neutropenia was 27% (Jada SR et al 2007). Furthermore, the presence of the 
UGT1A1*6 allele was associated with an approximately 3-fold increased risk of 
developing severe grade 4 neutropenia compared with the reference genotype group. 
These exploratory findings suggest that homozygosity for UGT1A1*6 allele may be 
associated with altered SN-38 disposition and may increase the risk of severe neutropenia 
in Asian cancer patients, particularly in the Chinese cancer patients who comprised 80% 
(n = 36) of the patient population in their study. 
  
The UGT1A1*28 variant is less frequent in Asians (15-49%) than Caucasians (50-66%), 
providing a basis for less toxicity from irinotecan treatment in Asians than Caucasians. 
There have been insufficient numbers of reports on the frequencies of other UGT variants 
according to race to assess their implications. 
Carboxylesterase and ABC transporters 
The two major forms of CES, CES1 and CES2, are mainly responsible for activation of 
irinotecan whilst the ABC transporter proteins (ABCB1, ABCC1, and ABCG2) are 
involved in the detoxification of xenobiotics substrates such as irinotecan. 
Polymorphisms for ABCB1, ABCC1, and ABCG2 as well as CES1 and CES2 have been 
described (Mathijssen et al 2003, de Jong et al 2004). Novel gene variants in ABCC1, 
ABCG2, CES1 and CES2 were identified and patients homozygous for the T allele of 
ABCB1 1236C>T were found to have increased levels of irinotecan and SN-38 
(Mathijssen et al 2003). The ABCG2 421C>A polymorphism was found to vary highly 
among different ethnic groups, with <1% variant alleles in Africans and up to 34% in 
Chinese (de Jong et al 2004). 
OXALIPLATIN 
Background and Mechanisms 
Oxaliplatin (EloxatinTM), in combination with 5-FU/FA, is currently indicated for first-
line (Europe/Australia/Asia) or second-line (US) therapy of metastatic colorectal cancer 
(Chau et al 2003). The drug has demonstrated response rates and progressive-free 
survival durations that were consistently equivalents or significantly higher than those in 
5-FU/FA (de Gramont et al 2000). 
 
Oxaliplatin is a third generation platinum analogue that induces DNA cross-linkages and 
apoptosis cell death. It is characterized by a diaminocyclohexane (DACH) moiety. As 
with other platinum compounds, the cytotoxicity of oxaliplatin appears to result from the 
inhibition of DNA synthesis due to the formation of intrastrand DNA adducts. Interstrand 
adducts are also observed although these constitutes less than 5% of all adducts (Culy et 
al 2000). Ultimately, these lead to the inhibition of DNA synthesis and repair and 
eventually apoptosis (Figure 3).  
 
Proteins implicated in the DNA repair response to oxaliplatin include excision repair 
complementation group 1 and 2 (ERCC1, ERCC2), X-ray cross complementation group 
1 (XRCC1) and glutathione S-transferases (GSTs). Polymorphisms in DNA repair genes 
may modify the repair capacity and result in variation in treatment efficacy and toxicity 
to platinum based therapy.  
Excision repair complementation group 1 (ERCC1) 
ERCC1 is a protein involved in DNA repair via nucleotide excision repair. A 
synonomous SNP ERCC1 19007 C>T (Asn118Asn) is associated with response and 
survival in patients with advanced CRC. In a retrospective study of patients with 
metastatic CRC, the response rate of patients receiving oxaliplatin/5-FU was significantly 
higher in patients with the genotype TT (61.9%) compared with those with genotypes CT 
(42.3%) and CC (21.4%) (Viguier et al. 2005). However in terms of survival, a study of 
106 patients with refractory advanced CRC receiving 5-FU/ oxaliplatin, patients with the 
genotype CC had improved survival compared with CT and TT genotypes (Park et al. 
2003, Stoehlmacher et al. 2004).  
 
In a healthy Chinese population, Yin et al. (2006) reported a 62% frequency of the TT 
genotype, significantly higher than the 41% (Moreno et al. 2006) and 40% (US, Weiss et 
al. 2005) observed in Caucasian populations. These results imply a better response but 
poorer survival rate for Asians from oxaliplatin-based treatment. 
Xeroderma pigmentosum group D (XPD/ERCC2) 
The XPD gene, also known as the excision repair complementation group 2 (ERCC2) 
gene, has a central role in DNA repair. Of the three common SNPs described in XPD, the 
XPD 751 A>C polymorphism is associated with clinical outcome to platinum 
chemotherapy in patients with advanced CRC. Patients with C genotype were less likely 
to have shorter disease progression and overall survival compared to other genotypes 
(Park et al 2001).  
 The AC/CC genotype is reportedly higher in Asians (95-100%) than in Caucasians (79-
87%) (Table 9) implying a shorter survival prospects for Asians from oxaliplatin-based 
therapy based on the XPD/ERCC2 751 A>C genotype. 
X-ray cross complementation group 1 
The XRCC1 protein is involved in DNA repair, base excision repair, oxidative damage 
and adducts formed after alkylating treatment. A common SNP in XRCC1 results in an 
amino acid substitution from Arg to Gln at codon 399 (exon 10, base G>A). An 
association between the XRCC1 399 G>A polymorphism and clinical response to 
oxaliplatin-based therapy in advanced CRC has been reported. Patients with the A allele 
had an increased risk of resistance to 5-FU and oxaliplatin chemotherapy. (Stoehlmacher 
et al 2001). 
 
A significant difference in the allelic frequency of XRCC1 399 G>A variant between the 
three major ethnic groups has been reported. In a meta-analysis involving 13,694 control 
subjects, the frequency of the A allele in European, Asian and African groups was 35%, 
27% and 16% respectively (p<0.0001) (Hu et al 2005). These trends are reflected in our 
review, in which the range of frequencies of the AA/AC genotypes are distinctly higher 
in Caucasians (47-68%) than Asians (40-46%). Taken together these frequencies project 
Asians to have a reduced risk of resistance to 5-FU and oxaliplatin based treatment. 
 
Glutathione S-transferase (GST) 
Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in 
detoxification by catalyzing the conjugation of many hydrophobic and electrophilic 
compounds with reduced glutathione. Stoehlmacher et al (2002) reported patients 
receiving oxaliplatin-based treatment, with the GSTP1 105 GG genotype survived a 
median of 24.9 months, those with the AG genotype a median of 13.3 months and those 
with the AA genotype a median of 7.9 months (P<.001). The GSTM1 and GSTT1 
genotypes were not associated with survival or clinical response.  
 
The frequency of GSTP1 105 GA/AA genotypes in Asians (30-37%) is lower than that of 




Genetic differences among the various racial and ethnic groups usually show the 
differences in the distribution of polymorphic traits which occur at different frequencies 
in different populations (Wood et al 2001) between and within the racial groups. 
However, such differences may be prevalent outside of genetics as well. 
 
For example, Iacopetta et al 2002 asked the question if there are two sides to colorectal 
cancer. And it appears that there might be two different genotype and phenotype resulting 
in a ‘proximal’ (caecum to splenic flexure) and ‘distal’ (descending colon to rectum) with 
the latter resulting in marginal 5-FU chemotherapy benefit. Such differences, however, 
may result in chemotherapy outcome. For instance, recently there has been strong 
evidence showing that Asians are more likely to have tumours in the distal colon (68.9%) 
compared to Caucasians (57.2%) (Chien et al 2005). 
 
Huang et al 2006 also presented an overaching , generic concept of cell phenotype  
regulation (non-genetic regulation). In it, they they provided a novel perspective onto the 
efficiency by which tumour cells acquire the tumour phenotype during tumour 
progression. The self-organising nature of dynamic cell regulator network (as opposed to 
pathway) and of the properties of the physical network of the cytoskeleton could account 
for the robustness and reliability with which random mutation drives the cell from a 
stable epithelial state to a malignant state. 
The underlying genetic determinants of the response to a drug, as well as the racial and 
ethnic differences in that response, are all beginning to be unraveled and understood. 
Indeed it appears to be based on the varying distributions of polymorphisms in drug 
receptors or drug metabolizing enzymes among the racial and ethnic groups. 
Polymorphisms of the enzymes which are responsible for the drug metabolism are 
distributed differently among the different racial and ethnic groups (Xie et al 2001).  
 
Dosage adjustments may be helpful in achieving a more optimal chemotherapeutic 
response outcome between Asians and Caucasians. A better understanding of this as well 
as the role of differing frequencies of genetic polymorphism between the races may lead 
to  better CROs in Asians. 
 
A meta-analysis performed by The Meta-Analysis Group in Cancer (Thirion et al 2004) 
showed an overall response (OR) rate of 17% (95% CI, 16% to 18%); median overall 
survival time at 11.1 months, toxicity rate at 22-31%. However, we also recognize that 
most of such phase III studies are of European or American origin 
 
We expect Asians to have significant reduced toxicity profile because of their low 
frequency of DPYD IVS14+1G>A. This is reinforced by our observations of phase II 
studies in both populations (Table 4). There is a suggestion with response and survival 
rates being marginalized as well. 
Extrapolating further, it is very likely we will experience similar variability with other 
cancer types (e.g. stomach) between Asians and Caucasians. 
 
In summary, we have identified a large number of published literature which shows the 
association (even causal pathways) between genetic polymorphisms with toxicity and 
response to chemotherapeutic agents commonly used in CRC, with the primary focus on 
differences between Asian and Caucasian populations. Perhaps it will not be too far off 
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TABLES 
Table 1. Frequency of DPYD*2A variants in different populations by race and health 
status 
Population Status Author Year Total GG GA AA %GG %GA %AA
CAUCASIAN
Caucasian population van Kuilenberg 2001 10000 9818 180 2 98.2 1.8 0.0
Caucasian population Raida 2001 851 843 8 0 99.0 0.9 0.0
Caucasian healthy Raida 2001 51 50 1 0 98.0 2.0 0.0
Caucasian CRC Raida 2001 39 38 1 0 97.0 2.6 0.0
Caucasian na Nauck 2001 250 244 6 0 97.6 2.4 0.0
British healthy Wei 1996 30 30 0 0 100.0 0.0 0.0
Finland screen Wei 1996 45 43 2 0 96.0 4.0 0.0
Caucasian healthy Ridge 1998 72 71 1 0 98.6 1.4 0.0
Caucasian healthy Verken 1996 50 50 0 0 100.0 0.0 0.0
ASIAN
Taiwan healthy Wei 1998 131 131 0 0 100.0 0.0 0.0
Japan healthy Wei 1998 90 90 0 0 100.0 0.0 0.0
Taiwan screen Wei 1996 36 34 2 0 95.0 5.0 0.0
OTHERS
African American healthy Wei 1998 105 105 0 0 100.0 0.0 0.0
 
Table 2. Frequency of TYMS-100 (TSER) variants in different populations by race and 
health status 
 
Population Status Author Year Total 2R2R 2R3R 3R3R %2R2R %2R3R %3R3R
CAUCASIAN
Italy Healthy Graziano 2004 139 31 74 31 22 54 22
Hungary Healthy Adleff 2004 102 18 59 25 18 57 25
USA Healthy Marsh 2000 104 20 56 28 19 54 27
USA Healthy Lightfoot 2005 755 181 364 205 24 48 27
British Healthy Marsh 2000 97 17 51 27 18 53 28
USA Healthy Skibola 2004 731 158 346 209 22 48 29
USA Healthy Shi 2005 1051 242 491 312 23 47 30
Caucasian Healthy Mandola 2003 99 19 44 36 19 44 36
Caucasian Healthy Marsh 1999 96 18 41 36 19 43 38
SW Australian Healthy Marsh 1999 95 15 42 38 16 44 40
ASIAN
Chinese Healthy Zhang 2004 348 13 107 223 4 31 64
Chinese Healthy Zhai 2006 473 25 143 305 5 30 65
Chinese Healthy Marsh 2000 96 2 30 64 2 31 67
Japan Healthy Luo 2002 21 2 2 17 10 19 71
Chinese Healthy Mandola 2003 80 2 34 64 3 43 80
Chinese Healthy Luo 2002 36 0 2 34 0 6 86
OTHER
African American Healthy Marsh 2000 92 18 49 22 20 53 24
African American Healthy Mandola 2003 99 29 38 33 29 38 33
Kenya Healthy Marsh 2000 98 17 43 25 17 44 26
Hispanic Healthy Mandola 2003 98 17 51 30 17 52 31
Ghania Healthy Marsh 2000 247 35 119 64 14 48 26
NON-HEALTHY
Hungary Colorectal ca. Adleff 2004 99 24 38 36 24 38 36
US NHL Skibola 2004 337 65 170 97 20 51 29
Italy Gastric ca. Graziano 2004 134 18 76 38 14 57 28
Chinese Esophageal ca. Zhang 2004 232 10 73 142 4 31 61
Chinese Breast ca. Zhai 2006 432 23 130 279 5 30 65
Chiliean hosp Acumo 2006 368 78 174 116 21 47 32
 
Table 3. Frequency of TYMS-58 G>C variants in different populations by race and health status 
Population Status Author Year Total 2R2R 2R3C 3C3C 2R3G 3C3G 3G3G %2R2R %2R3C %3C3C %2R3G %3C3G %3G3G
CAUCASIAN
Caucasian Healthy Mandola 2003 99 19 31 9 13 16 11 19 31 9 13 16 11
ASIAN
Japan Healthy Kawakami 2003 258 10 41 37 27 86 51 4 16 14 10 33 20
Chinese Healthy Mandola 2003 80 2 15 14 19 18 32 3 19 18 24 23 40
OTHERS
Afr. American Healthy Mandola 2003 59 29 13 2 25 12 19 49 22 3 42 20 32
 
Table 4. Frequency of TYMS 1494del6bp variants in different populations by race and 
health status 
 
Population Status Author Year Total DD DI II %DD %DI %II
CAUCASIAN
Italy healthy Graziano 2004 139 18 59 62 13 42 45
US healthy Skibola 2004 731 82 310 335 11 43 46
US healthy Shi 2005 1051 88 446 517 8 42 49
US healthy Lightfoot 2005 755 58 325 372 8 43 49
ASIAN
China healthy Zhai 2006 473 56 201 216 12 43 46
China healthy Zhang 2004 348 34 155 159 10 45 46
NON-HEALTHY
China breast CA Zhai 2006 432 30 208 194 7 48 45
China esophae Zhang 2004 232 23 107 102 10 46 44
Italy gastric Graziano 2004 134 22 73 39 17 54 29
US NHL Skibola 2004 337 23 144 166 7 43 50
 
Table 5. Frequency of MTHFR C677T variants in different populations by race and 
health status 
Population Status Author Year Total CC CT TT %CC %CT %TT
CAUCASIAN
Australia healthy Hamim 2002 225 24 113 88 11 50 39
Canada healthy Hamim 2002 414 59 183 172 14 44 42
Cau healthy Lin 2004 409 36 184 189 9 45 46
Cau healthy Lin 2004 410 50 164 196 12 40 48
England healthy Hamim 2002 222 29 97 96 13 44 43
Holland healthy Hamim 2002 503 45 234 224 9 47 45
Ireland healthy Hamim 2002 1309 141 568 600 11 43 46
Italy healthy Toffoli 2003 276 25 121 133 9 44 48
Italy healthy Hamim 2002 130 17 71 42 13 55 32
Italy healthy Hamim 2002 431 78 223 130 18 52 30
Italy healthy Toffoli 2003 279 56 140 83 20 50 30
Slovakia-caucasian healthy Gasparovic 2004 350 37 146 167 11 42 48
Slovakia-romania healthy Gasparovic 2004 146 19 68 59 13 47 40
US healthy Marchand 2004 2414 120 801 1493 5 33 62
US healthy Hughes 2006 50 3 22 25 6 44 50
US healthy Skibola 2004 722 71 310 341 10 43 47
US healthy Lightfoot 2005 755 83 316 356 10 42 47
US healthy Lightfoot 2005 755 77 331 347 11 44 46
US healthy Marchand 2004 2414 283 920 1211 12 38 50
US healthy Skibola 2004 722 84 350 288 12 48 40
US healthy Hughes 2006 50 6 19 25 12 38 50
US healthy Marchand 2005 2021 255 779 987 13 39 49
US (whts) healthy Keku 2002 539 51 223 265 9 41 49
US (whts) healthy Keku 2002 541 68 236 237 13 44 44
ASIAN
Chinese healthy Song 2001 360 5 113 242 1 31 67
Chinese healthy Shrubsole 2004 1208 40 344 824 3 29 68
Chinese healthy Hamim 2002 121 17 53 51 14 44 42
Chinese healthy Shrubsole 2004 1160 196 577 387 17 50 33
Chinese healthy Song 2001 360 62 172 126 17 48 35
Japan healthy Hamim 2002 244 32 116 96 13 48 39
Japan healthy Zuo 1999 115 18 46 51 16 40 44
Korea healthy Zuo 1999 124 9 82 33 7 66 27
Korea healthy Hamim 2002 124 9 82 33 7 66 27
OTHER
AfiAm healthy Hughes 2006 53 1 12 39 2 23 74
AfiAm healthy Hamim 2002 496 6 127 363 1 26 73
Afica-indian healthy Ranjith 2003 300 4 58 238 1 19 80
Afica-indian healthy Ranjith 2003 300 46 152 102 15 51 34
AfrAm healthy Lin 2004 21 3 9 9 14 43 43
AfrAm healthy Lin 2004 21 0 8 13 0 38 62
AfrAm healthy Hughes 2006 53 1 16 36 2 30 68
Arab healthy Khaled 2003 625 13 161 451 2 26 64
Arab healthy Khaled 2003 625 57 322 246 9 52 39
Argentina healthy Moora 2004 109 18 59 32 17 54 29
Argentina healthy Moora 2004 108 8 45 55 7 42 51
Brazil healthy Hamim 2002 129 10 42 77 8 33 60
Canada (Inuit) healthy Hamim 2002 174 2 17 155 1 10 89
Croatian healthy Lovricevic 2004 228 21 102 105 9 45 46
HispAm healthy Lin 2004 17 0 4 13 0 24 77
HispAm healthy Lin 2004 17 1 5 11 6 29 65
India healthy Wang 2006 291 0 36 255 0 12 88
India healthy Wang 2006 291 51 135 105 18 46 36
Indian healthy Kumar 2005 202 6 49 147 3 24 73
Indian healthy Kumar 2005 106 3 23 80 3 22 76
Indian healthy Kumar 2005 106 21 59 26 20 56 25
Indonesia healthy Hamim 2002 68 0 11 57 0 16 84
Mexico healthy Hamim 2002 250 87 119 44 35 48 18
S Africa healthy Hamim 2002 107 0 22 85 0 21 79
Sub Sahara healthy Hamim 2002 301 0 38 263 0 13 87
Turkey healthy Zeybuk 2006 144 15 10
US (hisp) healthy Hamim 2002 169 35 71 63 21 42 37
NON-HEALTHY
India rectum Wang 2006 243 2 37 204 1 15 84
India rectum Wang 2006 243 26 108 109 11 44 45
India colon Wang 2006 59 0 6 53 0 10 90
India colon Wang 2006 59 5 22 32 9 37 54
Italy crc Toffoli 2003 276 38 145 93 14 53 34
Italy crc Toffoli 2003 276 25 129 122 9 47 44
Turkey crc Zeybuk 2006 52 7 27 18 14 52 35
Turkey gastric Zeybuk 2006 35 5 14
US NHL Skibola 2004 334 52 160 122 16 48 37
US NHL Skibola 2004 333 27 128 178 8 38 53
US (whts) crc Keku 2003 309 24 140 144 8 46 47
US (whts) crc Keku 2003 309 21 132 156 7 43 51
 
Table 6. Frequency of MTHFR A1298C variants in different populations by race and 
health status 
Population Status Author Year Total AA AC CC %AA %AC %CC
CAUCASIAN
Cau healthy Lin 2004 409 36 184 189 9 45 46
Italy healthy Toffoli 2003 276 25 121 133 9 44 48
US healthy Lightfoot 2005 755 77 331 347 11 44 46
US healthy Skibola 2004 722 71 310 341 10 43 47
US healthy Hughes 2006 50 6 19 25 12 38 50
US healthy Marchand 2004 2414 120 801 1493 5 33 62
US healthy Keku 2002 541 68 236 237 13 44 44
ASIAN
China healthy Song 2001 360 5 113 242 1 31 67
China healthy Shrubsole 2004 1208 40 344 824 3 29 68
OTHER
Afica-indian healthy Ranjith 2003 300 46 152 102 15 51 34
AfrAm healthy Lin 2004 21 0 8 13 0 38 62
AfrAm healthy Hughes 2006 53 1 16 36 2 30 68
Arab healthy Khaled 2003 625 57 322 246 9 52 39
Argentina healthy Moora 2004 108 8 45 55 7 42 51
HispAm healthy Lin 2004 17 1 5 11 6 29 65
India healthy Wang 2006 291 51 135 105 18 46 36
Indian healthy Kumar 2005 106 21 59 26 20 56 25
NON-HEALTHY
India colon Wang 2006 59 5 22 32 9 37 54
India rectum Wang 2006 243 26 108 109 11 44 45
Italy crc Toffoli 2003 276 25 129 122 9 47 44
US NHL Skibola 2004 333 27 128 178 8 38 53
US (whts) crc Keku 2003 309 21 132 156 7 43 51
 
Table 7. Frequency of UGT1A1*28 variants in different populations by race and health status 
 
Population Status Author Year Total 56 57 66 67 68 77 78 %56 %57 %66 %67 %68 %77 %78
CAUCASIAN
Scottish healthy Monoghan 1996 77 0 0 31 37 0 9 0 0 0 40 48 0 12 0
German healthy Kohle 2003 1000 0 0 500 420 0 80 0 0 0 50 42 0 8 0
European healthy Beutler 1998 71 0 0 24 39 0 8 0 0 0 34 55 0 11 0
ASIAN
Asian healthy Beutler 1998 47 0 0 33 13 0 1 0 0 0 70 28 0 2 0
China healthy Zhong 2006 na na na na na na na na na na 71 28 na 1
China healthy Zhong 2006 na na na na na na na na na na 77 22 na 1
China healthy Zhong 2006 na na na na na na na na na na 85 15 na 0
Chinese healthy Balram 2002 89 0 0 71 27 0 2 0 0 0 80 30 0 2 0
Indian healthy Balram 2002 84 0 0 43 44 0 13 0 0 0 51 52 0 15 0
Japanese healthy Ando 1998 58 0 0 44 12 0 2 0 0 0 76 21 0 3 0
Korean healthy Kim 2002 20 0 0 17 2 0 1 0 0 0 85 10 0 5 0
Malay healthy Balram 2002 93 0 0 67 29 0 4 0 0 0 72 31 0 4 0
OTHERS
Egyptian healthy Kohle 2003 50 0 0 28 18 0 4 0 0 0 56 36 0 8 0
African Americans healthy Beutler 1998 101 2 5 26 37 4 19 6 2 5 26 37 4 19 6
Gambians healthy Hall 1999 36 5 3 7 10 1 7 3 14 8 19 28 3 19 8
Africans healthy Hall 1999 40 1 3 9 17 4 5 1 3 8 23 43 10 13 3
Ewondo healthy Hall 1999 10 1 1 3 5 0 0 0 10 10 30 50 0 0 0
 
Table 8. Frequency of ERCC1 19007 (Asn118Asn) variants in different populations by 
race and health status 
 
Population Status Author Year Total CC CT TT %CC %CT %TT
CAUCASIAN
Spain healthy Moreno 2006 301 52 126 123 17 42 41
US healthy Weiss 2005 420 54 196 170 13 47 40
ASIAN
China healthy Yin 2006 143 4 50 89 3 35 62
OTHERS
China lung Yin 2006 151 9 44 98 6 29 65
Spain lung Moreno 2006 334 64 138 132 19 41 40
 
Table 9. Frequency of XPD/ERCC2 751 variants in different populations by race and 
health status 
Population Status Author Year Total AA AC CC %AA %AC %CC
CAUCASIAN
Whites healthy Wrensch 2005 432 55 213 164 13 49 38
US healthy Weiss 2005 420 64 197 159 15 47 38
Oslo healthy Zienolddniy 2005 386 82 121 183 21 31 47
ASIAN
China healthy Shen 2005 118 0 11 107 0 9 91
China healthy Liang 2003 1020 6 166 848 1 16 83
Asian healthy Wrensch 2005 19 1 2 16 5 11 84
OTHERS
African Amercans healthy Wrensch 2005 13 1 9 3 8 69 23
Latinos healthy Wrensch 2005 25 1 9 15 4 36 60
China lung Liang 2003 1006 14 153 839 1 15 83
 
Table 10. Frequency of XRCC1 399 variants in different populations by race and health 
status 
Population Status Author Year Total GG GA AA %GG %GA %AA
CAUCASIAN
Belgian healthy Wood 2001 31 10 17 4 32 55 13
Brazil healthy Rossit 2002 96 47 33 12 49 34 13
Brazil healthy Duarte 2005 150 70 57 23 47 38 15
US healthy Olshan 2002 161 62 82 17 39 51 11
Turkey healthy Kocabas 2006 166 62 75 29 37 45 18
Portugal healthy Varzim 2003 178 80 80 18 45 45 10
Italian healthy Shen 2003 214 92 98 24 43 46 11
Germany healthy Sanyal 2004 246 113 111 22 46 45 9
Finland healthy Misra 2003 313 154 130 29 49 42 9
Oslo healthy Zienolddniy 2005 391 151 186 54 39 48 14
US healthy Kiffmeyer 2004 407 181 187 39 45 46 10
US healthy Duell 2002 860 413 344 103 48 40 12
US healthy Zhou 2003 1240 552 552 112 45 45 9
ASIAN
US (asian) healthy Duell 2002 53 30 17 5 57 33 10
Korea healthy Park 2002 135 81 48 6 60 36 4
Korea healthy Wu 2004 196 114 73 10 58 37 5
Korea healthy Ito 2004 448 253 169 26 57 38 6
China healthy Cao 511 270 201 30 54 40 6
Korea healthy Yeh 2005 736 417 266 53 57 36 7
OTHERS
US (Afr. Amer.) healthy Duell 2002 36 25 11 0 69 31 0
China NPC Cao 462 241 152 32 57 36 8
 
 
Table 11. Frequency of GSTP1 105 G>A variants in different populations by race and 
health status 
Population Status Author Year Total GG AG AA %GG %AG %AA
CAUCASIAN
Finland healthy Voho 2006 2079 1080 827 172 52 40 8
Sweden healthy Sun 2005 255 127 101 27 50 40 10
Brazil (whites) healthy Rossini 2002 319 164 109 46 51 34 14
ASIAN
Japan healthy Wang 2003 119 84 34 1 71 29 1
China healthy Wang 2003 38 24 13 1 63 34 3
OTHERS
India healthy Soya 2005 NA NA NA NA 44 47 9
Brazil (non-whites) healthy Rossini 2002 272 130 116 26 48 43 10
Japan lung Wang 2003 112 67 45 1 60 39 1
Sweden colorectal ca. Sun 2005 125 59 51 15 47 41 12
 
 
Table 12. Treatment-related outcomes associated with various genotypes, their frequencies in Caucasians and Asians, and the 
implications of frequency differences to the chemotherapy-related outcomes of Asians 
 
Variant Outcome Association % Caucasians % Asians Implication for Asians
Fluoropyrimidines
DPYD*2A more toxicity 0-4 0-5 inconclusive
TYMS (-100) 2R>3R less toxicity, worse response 22-38 40-86 less toxicity, worse response
TYMS (-58) low>high lack of 5FU benefit 40 64-86 less benefit from 5FU
TYMS (+1494) del>ins worse survival 45-49 46-46 no difference
MTHFR 677 C>T lower response 30-62 27-68 no difference
MTHFR 1298 A>C worse survival 44-62 67-68 worse survival
Irinotecan
UGT1A1*28 more toxicity 50-66 15-49 less toxicity
Platinum Agents
ERCC1 118 C>T better response, worse survival 40-41 62 better response, worse survival
ERCC2 751 A>C worse survival 79-87 95-100 worse survival
XRCC1 399 G>A increased resistance 9-18 40-46 reduced resistance




Figure 1 (fluoropyrimdines) 
Figure 2 (irinotecan) 







 Figure 1: Metabolism of Fluoropyrimidine 
    Figure 2: Metabolism of Irinotecan 
  Figure 3: Metabolism of oxaliplantin 
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ABSTRACT 
Background: In a recent review, our group showed data which suggested that the 
differences between chemotherapy related outcomes (CROs) between races may be due 
to the frequencies of chemotherapy related genotypes given a standardized dosing 
regime. However, to date, there are still no large scale studies comparing CROs between 
Asians and Caucasians. In this study, we test the hypothesis that CROs in colorectal 
cancer (CRC) patients will differ between Asians and Caucasians.  
 
Materials and Methods: A meta-analysis was conducted in 2006. It was based on Phase 
II trials and all forms of FP administration were considered. Toxicity, response and 
overall survival rates were considered as endpoints. STATA ver. 8 was used for statistical 
evaluation of results.  
 
Results: There are 15 Asian and 22 Caucasian studies with a total of 2075 patients. In 
total there were 38 eligible regimes. Analysis of toxicity – diarrhea In Asians, the 
frequency was 5.3% [2.9%-7.7%] while that the Caucasian series was 21.7% [16.1%-
27.2%]. Analysis of toxicity – nausea and/or vomiting The frequency of toxicity between 
Asians vs Caucasians was 3.0% [1.3%-4.8%] vs 7.9% [5.5%-10.4%]. Analysis of toxicity 
– stomatitis In Asians, the frequency was 5.3% [2.9%-7.7%] while that the Caucasian 
series was 14.9% [9.7%-20.1%]. Analysis of response Tumour response was found in 
31.6% [26.6%-36.6] of Asian patients while Caucasian patients having 32.0% [29.0%-
35.0%]. Analysis of survival In Asians, the median was 12.6 months [9.5 months – 15.6 
months] while that the Caucasian series was 14.3 [11.8 months – 16.8 months].  
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 Conclusion: Clinical outcome differences between Asians and Caucasians suggest that 
using a ‘standard’ regimen for all may not be the most appropriate strategy. Prospective 
studies that compare clinical outcomes between Asians and Caucasians in a single study 
may be the most suitable to seek a better understanding of the differences in CROs. 
 
INTRODUCTION 
Traditionally, application of chemotherapy regimens in Asian populations has followed a 
route of development on Caucasian populations (US or Europe) followed by small 
equivalence studies to establish adequate safety in Asian populations. While a proven 
approach, the lack of development on Asian populations has always left open the 
question of whether current regimens could be further optimized for Asians (Kawahara et 
al 2007). 
 
In the last decade, pharmacogenetics has established significant links between a number 
of genotypes (“chemoresponse genotypes”) and outcome from certain chemotherapeutic 
agents. These links often have been supported by a rational molecular basis, with the 
genotypes having functional effects on drug transport, metabolism or activity 
(Ploylearmsaeng et al 2006). 
 
In a recent review (Chua et al, manuscript in preparation), we noted significant 
differences in the frequencies of many chemoresponse genotypes between Asians and 
Caucasians for agents used in the treatment of CRC. The data implied that differences in 
chemotherapy related outcomes could be expected between Asians and Caucasians given 
standardized dosing and scheduling. However, there are currently no large-scale studies 
comparing patient outcomes from CRC chemotherapy in Asians and Caucasians to 
evaluate if the implications are true. 
 
The objective of this study was to test the hypothesis that outcome rates (toxicity, 
response and survival rates) in CRC patients treated with fluoropyrimdines (FPs) will 
differ between Asians and Caucasians, based on differences in the frequencies of 
chemoresponse genotypes between the two races. FPs, including 5-fluorouracil, 
capecitabine, tegafur-uracil (UFT) and S-1, were selected as the initial focus, as they are 
the most commonly used agents in CRC chemotherapy. 
 
MATERIALS AND METHODS 
Eligible trials 
The present meta-analysis is based on Phase II trials conducted in Asian (Japan, Taiwan, 
Singapore, Thailand) and Caucasian (Europe and America) populations. Phase III were 
not considered for comparison since there were no such trials conducted on Asian 
populations. Relevant trials were selected by searching PUBMED for the period between 
January 1991 and December 2004. Key terms included:  5-FU AND Phase II  AND 
Colorectal cancer, Capcitabine AND Phase II AND Colorectal cancer, UFT AND Phase 
II AND Colorectal cancer, Tegafur AND Phase II AND Colorectal cancer, AND Asian, 
OR Asia, OR Japan, OR Taiwan, OR China, OR Korea, OR India, OR United States, OR 
Europe, OR Caucasian. 
 
Trials using all forms of FP administration were considered. These included trials using 
5-FU, UFT, capecitabine or S-1 with different schedules and dosages. All other forms of 
modifiers such as leucovorin were allowed for assessment. Series of patients having prior 
chemotherapy were not considered. Two studies selected patients on the basis of older 
age; these were also not considered due to their potential bias. The selection of trials can 
be seen in Figure 1. 
 
Protocol for meta-analysis 
In 2006, a protocol for the meta-analysis was established. Group data from each study 
was searched and information on toxicity, response and/or median overall survival rates 
was collected. Only data from the analysis of primary tumors were included in the 
selection. Toxicity rates were based on grade 3/4 toxicity (WHO or NCI scale) 
frequencies and response rates were based on the proportion of subjects with complete 
and partial response. 
 
The common toxicity criteria (CTC) differs somewhat between the WHO, ECOG and 
NCI grading scale. Even within the NCI grading system, there are different versions 
depending on the publication date of the descriptive terminology that can be utilized for 
Adverse Events (AE). For our meta-analysis, we have decided to term all Grade 3 
toxicity and above as severe AE. Hence depending on the different criteria (CTC) being 
used, there may be slight nuances. For example, comparing diarrhea, severe toxicity 
(grade 3 and above) may include NCI (CTC ver 3) which includes  >7 loose stools/day 
and death (grade5), NCI (CTC ver 1) which includes 7-9 loose stools/day, and WHO >7 
loose stools/day (no death). It was unfortunate we were not able to obtain the raw data to 
stratify the analysis accordingly. 
 
In general, the key definitions of response used in the various studies were similar 
between the various studies. Completed response (CR) was defined as disappearance of 
all objective evidence of disease lasting for more than 4 weeks. Partial response (PR) was 
defined as a decrease of 50% or greater than 50% in the measurable lesion lasting for 
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more than 4 week. Progressive disease (PD) was defined was defined as an increase of 
25% or greater than 25% in the measurable lesion lasting for more than 4 week. All other 
patients are considered to have stable disease. 
 
Statistical analysis 
All statistical analyses were performed using STATA ver.8. Differences in frequencies 
were evaluated using the Pearson’s chi-square test and the resampling method used for 
estimation of the 95% CI for the binomial endpoints. Test for heterogeneity was 
evaluated using the Q test and the random model was employed.  The funnel plot of the 
standard error of the effect estimate were plotted against the effect estimates (eg response 
rate) to evaluate the possibility of publication bias.  
RESULTS 
Eligible trials 
Our search identified 38 eligible studies since 2006 with a total of 2075 patients (Table 
1). There were 15 studies on Asian populations and 22 on Caucasian populations. Shirao 
et al 2004 [US] provided data on both an Asian and Caucasian population and hence it 
was considered as 2 studies, 1 from Asia and the other Caucasian.. In 3 of the studies 
(Wang et al 1996 [Taiwan], van Cutsem et al 2000 [Belgium], Adimi et al 2001 
[Denmark], multiple regimens were assessed. Each of these regimens was considered as a 
separate data series, altogether amounting to seven data series from the 3 studies. 
Altogether, there were 43 data series (Table 1). 
 
Overall, the age ranges were between 23 – 79 years and 21 – 88 years for the Asian and 
Caucasian populations respectively. The male:female ratio was 1.65:1.00 for the Asian 
populations and 1.50:1.00 for the Caucasian populations.  
 
Publication bias 
Assessment of publication bias was assessed using the funnel plot. In all, 43 date series 
were examined for the presence of publication bias in our study. The 43 data series were 
also subdivided into Asian and Caucasian studies and response rate was considered as the 
treatment effect. Figure 2 shows the graphical funnel plot.  
 
In general, no asymmetry was detected in the funnel plot, which suggests that there is no 
inherent bias in the study.  When Asian studies only are assessed, there are higher 
standard error rates. This is most likely due to the fact that Asian studies typically have 
lower sample size. 
 
Analysis of toxicity 
Analysis of toxicity rates was restricted to analysis of rates diarrhea, nausea and/or 
vomiting, and stomatitis, as these were the symptoms more consistently reported on. 
Analysis of toxicity - diarrhea 
The overall frequency of grade 3/4 diarrhea in all the 35 Asian and Caucasian data series 
reporting such information was 16.5% [95% confidence interval 12.6%-20.4%, Figure3). 
In Asian series alone, the frequency was 5.3% [2.9%-7.7%, n=11], which is significantly 
lower than that of the Caucasian series (21.7% [16.1%-27.2%], n=24). The data series 
were significantly heterogenous overall (Q=290.294, p<0.001) and in the Caucasian 
subgroup (Q=236.761, p<0.001). The Asian data series were homogenous (Q=290.294, 
p=0.233). 
Analysis of toxicity – nausea and/or vomiting 
Overall, the frequency of grade 3/4 nausea and/or vomiting was 6.4% [4.6%-8.1%] 
(n=31, Figure 4). Similar to the results on diarrhea, Asians (3.0% [1.3%-4.8%], n=9) had 
a significantly lower frequency of nausea and/or vomiting than Caucasians (7.9% [5.5% 
to 10.4%], n=22). The overall (Q=77.433, p<0.001) and Caucasian (Q=68.172, p<0.001) 
data series were significantly heterogeneous, while the Asian series (Q=4.304, p=0.829) 
were not. 
Analysis of toxicity - stomatitis 
The frequency of grade 3/4 stomatitis in both Asian and Caucasian series combined was 
11.7% [8.1%-15.3%] (n=23, Figure 5). In the Asian series (5.3% [2.6%-7.9%], n=7), the 
frequency was significantly lower than that of Caucasians (14.9% [9.7%- 20.1%], n=16).  
The overall (Q=109.662, p<0.001) and Caucasian (Q=99.295, p<0.001) series were 
significantly heterogeneous, while the Asian series (Q=3.411, p=0.756) were not. 
Analysis of response 
The overall frequency of clinical response was 31.8% (29.2%-34.4%) in the 43 Asian and 
Caucasian data series reporting on this parameter (Figure 6). The response rate in Asian 
data series (31.6% [26.6% to 36.6%], n=17) was not significantly different from that of 
Caucasian series (32.0% [29.0%-35.0%], n=26). The overall (Q=66.009, p=0.010) and 
Asian (Q=29.378, p=0.022) data series were heterogeneous. The Caucasian data series 
were marginally homogeneous (Q=36.469, p=0.065). 
Analysis of survival 
Of the 43 eligible data series, 15 reported information suitable for survival analysis. 
Overall, the median survival time was 13.6 (11.4-15.7) months (Figure 7). The median 
survival time was marginally lower in the Asians series (12.6(9.5-15.6) months, n=7) 
than the Caucasian series (14.3 [11.8-16.8] months, n=8). The Caucasian (Q=73.817, 
p<0.001), Asian (Q=54.450, p<0.001) and combined (Q=155.873, p<0.001) series were 
all heterogeneous with respect to survival time. 
 
DISCUSSION 
In a recent review (Chua et al., manuscript in preparation), we found evidence implying 
Asians could be expected to have lower frequencies of toxicity, response and survival 
compared to Caucasians from FP treatment. The TYMS (-100) 2R>3R genotype, 
associated with lower FP toxicity and response (Marsh et al 2001), is more frequent in 
Asians (40-86%) than Caucasians (22-38%). The TYMS (-58) G>C genotype, linked to 
improved patient survival benefit from 5-FU treatment (Kawakami et al 2003), is also 
more frequently in Asians than Caucasians.  
 
The results from this meta-analysis of 38 studies have shown Asians to have significantly 
lower toxicity rates to Caucasians receiving FP-based treatment (Figures 1-3), but no 
difference in response (Figure 4) or survival (Figure 5) rates. With respect to toxicity, the 
results of this study are consistent with the genotype-based implications. However, in 
terms of response and survival, the results do not concur. 
 
These meta-analysis results are similar to those of Shirao et al. (2003). Investigating 44 
Japanese and 45 Americans given a standardized UFT and leucovorin regimen, Shirao et 
al. (2003) noted significant differences in the frequency of grade 3/4 diarrhea (9 vs 22%) 
but not response (36% vs 34%) between the two groups. To our knowledge, this is the 
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only other study that has systematically compared fluoropyrimidine-related outcomes 
between Asians and Caucasians 
 
In many ways, the varied concordance of genotype implications and outcome endpoint 
could be expected. It is considered that for response and survival, tumour-specific 
features, such as tumour suppressor gene and oncogene activity, are likely more dominant 
determinants than germline genotypes. With toxicity being a more systemic phenotype, 
host features, such as germline genotypes, are likely to be a more significant factor. 
These results hence further reinforce the dogma that toxicity is host dependent and 
response and survival are more dependent on tumour features. 
 
Further evidence to the dogma of toxicity being host (germline genotype) dependent and 
response and survival being tumour dependent could be interpreted from the latter result. 
The dogma could explain the homogeneity for toxicity but not response and survival in 
Asian series. The homogeneity for Asian but not Caucasian series in toxicity frequencies 
could be accounted for by the “Out of Africa” theory (Jorde et al. 1998). The “Out of 
Africa” theory maintains that Asians derived from a later evolutionary group to 
Caucasians and hence have a less variable gene pool and be expected to be more 
homogeneous. 
 
Our analysis also revealed there to be significant heterogeneity in each of the series types 
for most end-points, indicating caution should be taken in interpreting the trends 
observed. The combined Asian and Caucasian series, as well as the Caucasian series 
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alone, were heterogeneous for all endpoints examined. The Asian series were also 
heterogeneous for response and survival, however were homogeneous for each of the 
three toxicity endpoints. 
 
Our discussion of heterogeneity begins with whether it is reasonable to believe that one overall 
estimate applies to all the studies encompassed. In our analysis (Figures 1-3), it is visually clear 
that there is strong evidence that Asians are more homogeneous with regards to toxicity compared 
to Caucasians, which were heterogeneous. In other words, there is strong heterogeneity between 
Asians and Caucasians with regards to host features. 
 
In this paper, it is possible that sources of heterogeneity may have been introduced by 
characteristic of the design and conduct of the studies. Even then, it may often be difficult 
to explain heterogeneity. For example, (Owen et al., 2003) carried out a review of the 
effect of breast feeding in infancy on blood pressure in later life. Although there was 
clear heterogeneity, the authors were unable to explain it. The obvious candidate 
explanatory variable, the age at which the blood pressure was measured, was unable to 
explain the heterogeneity. Under these circumstances, the authors accept the existence of 
the heterogeneity and say that the greater uncertainty that this adds to their estimate 
should be reflected in the method of estimation and calculation of the confidence interval. 
For our study, we did this using a random effects model, where we regard each study as 
estimating a different effect. 
 
Response to antidepressants vary considerably between patients treated with similar 
dosages. Most antidepressants and also antipsychotics are metabolized by the 
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polymorphic debrisoquine/sparteine hydroxylase, i.e., cytochrome P450 (CYP). About 
7% of Caucasians are poor metabolizers and such patients might develop adverse drug 
reactions when treated with recommended doses of, for example, tricyclic 
antidepressants. In contrast, ultrarapid metabolizers with multiple CYP2D6 genes might 
require high doses of such drugs for optimal therapy. The mean CYP2D6 activity is 
lower in Oriental than in Caucasian populations, because of a frequent mutation causing 
decreased enzyme activity. Drugs metabolized by the same enzyme may interact with 
each other (Bertilsson et al. 1999). 
 
Recently, exact mechanism of calcium hypersensitivity of spastic vascular smooth 
muscle have been reported. In animal models with coronary spasm Rho-kinase is 
upregulated at the spastic site and plays a key role in inducing vascular smooth muscle 
hypercontraction by inhibiting myosin light chain phosphatase, resulting in enhancement 
of its phosphorylation. Also, oxidative stress has been given attention as an important 
mediator of the spastic conversion of vascular smooth muscle cell "phenotype." The 
incidence of coronary spastic angina in the Japanese population is reported to be 
remarkably high compared with that in Caucasians. Clinical and pathophysiological 
differences between Japanese and Caucasian patients with respect to coronary vasospasm 
are characterized by a lower prevalence of fixed coronary artery stenoses and diffuse 
coronary hyperreactivity in the Japanese patients. Recently, several distinct 
characteristics have been recognized to be associated with coronary vasospasm in studies 
analyzing data obtained from Japanese patients. (Miwa et al. 2005) On occasions, their 
findings have been at variance with those undertaken on caucasian patients, raising 
speculation that vasomotor differences between races may exist. (Beltrame. et al 1999)  
 
Our laboratory has also linked differences in warfarin maintenance requirements between 
Chinese, Malays and Indians to differences in frequencies of haplotypes of the gene 
encoding VKORC1, a target of warfarin (Lee et al. 2005). Taken together, these results 
suggest serious consideration of the systems for drug administration to different racial 
populations is warranted. 
 
Limitations 
It is important to note that this study has many limitations. To obtain enough series and 
sample numbers for analysis, we considered all types of FPs administered in various 
doses, schedules and with various modulators (such as leucovorin) in our analysis, even 
though all these factors are believed to influence the efficacy of FP treatment. Due to a 
lack of Phase III Asian trials, our data is based on Phase II data even though the goals of 
Phase III trials make their data more appropriate. Moreover, in such Phase II, not all the 
endpoints were reported on in many series, making for inconsistent endpoint 
comparisons. This is particularly pertinent to toxicity endpoints, which are only 
represented by three types in this study – diarrhea, nausea and/or vomiting and stomatitis.  
 
The generalization of country data to represent “Asian” and “Caucasian” data is 
imperfect also. The uneven numbers of reports from representative countries, such as 
Asian data being mainly derived from Japan and Taiwan, could also provide a source of 
bias. Of the 17 Asian data series, 5 studies (30%) were from Taiwan and 8 (47%) were 
from Japan. Together they made up 77% (13/17) of all Asian studies. 
 
It should be noted that although funnel plots have traditionally been used to examine 
evidence for publication bias, funnel plot asymmetry may reflect other types of bias as 
well. They should thus be seen as displaying the evidence for other bias such as selection 
biasness in general rather than publication bias in particular (Egger et al. 1997).  
 
Significant analysis was also spent on heterogeneity. Our approach to understanding 
heterogeneity in our data is to include a wide range of studies, but then examine the 
sensitivity of the results by looking at more narrowly drawn subsets of the studies.  
 
Different data sets resulted in different nuances. For example, Yeh et al defined  CR as 
disappearance of all objective evidence of disease, including all necessary imaging 
studies, lasting for more than 4 weeks. On the other hand, Cure et al defined CR as 
disappearance of all signs and symptoms lasting for more than 9 weeks. The grading of 
toxicity is also potentially skewed, coming from reports using a mixture of WHO and 
NCI toxicity criteria. Such differences may also result in a source of heterogeneity in the 
results. 
 
In meta-analysis, when the differences in results between studies is greater than would be 
expected by chance, we may need to investigate whether the observed variation in results 
across studies is associated with clinical and/or methodological differences between 
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studies. In fact, an uncritical use of the technique can be very misleading. Hence, exploring 
the possible reasons for heterogeneity between studies is an important aspect in 
conducting a meta-analysis. 
 
It is widely accepted that the robustness of a meta-analysis be examined in a thorough 
sensitivity analysis. In many ways, we conducted our sensitivity analysis by calculating 
the overall effect size in toxicity, response and survival. We then stratified this effect size 
into ‘Asian’ and ‘Caucasian’ groups. Other more conventional methods that could have 
been performed include applying the meta-analytic approach to subsets of the K studies, 
and/or applying the leave-one-out method. Other than invoke the leave-one-out method, 
other methods may also include a sensitivity analysis by applying the meta-analysis to 
subsets of studies based on high-quality versus low-quality studies. 
 
We did not conduct any further subgroup analysis since the primary study was an 
assessment between Asians and Caucasians 
 
In summary, the results of this study have indicated that Asians do differ from 
Caucasians in their outcome from FP treatment, albeit only in frequencies of toxicity and 
not response or survival. The toxicity differences were consistent with those implied by 
response genotype frequency differences between the two races, suggesting 
characterization of the genotype frequency differences between races could be a valid 
step in predicting likely inter-racial drug handling capabilities. The predictive capability 
did not appear to extend to prognosticating tumor-dependent endpoints, such as response 
or survival, however; re-affirming known dogmas of genotype-phenotype penetrance. 
Given this study has been reliant on heterogeneously treated and annotated Phase II trials, 
future studies verifying these preliminary findings in a standardized multi-racial phase III 
trial would appear warranted. Also, with toxicity frequencies integral to determining 
optimal drug dosing, studies investigating the benefit of dose adjustment for Asians 
would also be of keen interest. The results of this study provides further proof to a 
growing volume of evidence indicating that differences in treatment-response genotype 
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TABLES 
Table 1. Phase II studies on fluoropyrimdines reporting on toxicity and response rates and survival times according to race 













Tan 1996 Singapore Asian 26 5FU 250 0 0 0 46 NA
Wang 1996 Taiwan Asian 36 5FU 425 6 6 3 19 18
Matsumura 2001 Japan Asian 42 5FU 600 12 0 2 36 13
Yang 2001 Taiwan Asian 26 5FU 1200-2200 0 4 4 27 12
Yang 1999 Taiwan Asian 36 5FU 2600 0 0 3 47 12
Yeh 1997 Taiwan Asian 42 5FU 2600 5 5 7 43 10
Wang 1996 Taiwan Asian 36 5FU 3000 3 0 6 14 21
Kondo 2004 Japan Asian 22 CAPE 1656 0 NA 0 25 13
Sakamoto 2004 Japan Asian 60 CAPE 1656 0 NA NA 27 18
Ichikawa 2000 Japan Asian 20 UFT 400 10 5 NA 35 8
Shirao 2004 Japan Asian 44 UFT 300 9 4 0 36 NA
Lin 2000 Taiwan Asian 40 UFT 300 10 0 5 33 NA
Yang 2002 Taiwan Asian 51 UFT 300 14 4 2 30 17
Thongprasert 2000 Thailand Asian 20 UFT 350 NA NA NA 22 NA
Keizo 1999 Japan Asian 30 S-1 100 10 7 NA 17 12
Ohtsu 2000 Japan Asian 63 S-1 80 2 0 2 36 12
Shirao 2004 Japan Asian 38 S-1 80 3 0 0 40 12
Sinnige 1992 Netherlands Caucasian 21 5FU 200 0 0 0 24 15
Labianca 1994 Italy Caucasian 63 5FU 400 8 11 2 27 13
Ychou 2003 France Caucasian 53 5FU 400-600 2 4 2 37 19
Fried 1995 Israel Caucasian 56 5FU 425 11 27 NA 33 9
Blanke 1997 US Caucasian 36 5FU 500 58 NA 33 41 13
Tomlinson 2002 US Caucasian 97 5FU 600 25 38 12 31 13
Cure 2000 France Caucasian 28 5FU 600-800 NA NA 2 29 13
Focan 2000 Belgium Caucasian 60 5FU 700 8 3 5 47 15
Sdrobolini 2000 Italy Caucasian 22 5FU 750 23 18 5 25 14
Wadler 1991 US Caucasian 38 5FU 750 22 6 3 42 18
Cure 2002 France Caucasian 100 5FU 900-1100 21 26 12 41 17
Aranda 1999 Spain Caucasian 110 5FU 1600 25 9 13 38 15
Fahlke 1999 Germany Caucasian 15 5FU 2600 13 20 0 33 NA
Hartung 2001 Germany Caucasian 51 5FU 2600 22 8 4 37 17
Aranda 1995 Spain Caucasian 43 5FU 3500 58 26 16 29 15
van Cutsem 2000 Belgium Caucasian 39 CAPE 1331 13 0 8 21 NA
van Cutsem 2000 Belgium Caucasian 35 CAPE 1657 57 9 17 23 NA
van Cutsem 2000 Belgium Caucasian 34 CAPE 2150 27 9 18 24 NA
Adimi 2001 Denmark Caucasian 63 CAPE 2500 3 NA NA 23 11
Rao 2004 UK Caucasian 84 CAPE 2500 10 0 2 38 14
Adimi 2001 Denmark Caucasian 77 UFT 300 9 NA 4 22 11
Gyldenkerne 2004 Denmark Caucasian 97 UFT 250-300 7 NA 7 27 13
Gonzalez 1995 Spain Caucasian 75 UFT 390 9 4 4 39 14
Pazdur 1997 US Caucasian 45 UFT 350 11 0 5 42 NA
Shirao 2003 US Caucasian 45 UFT 300 22 0 4 34 NA
Brande 2003 France Caucasian 47 S-1 80 38 NA 15 24 NA
 
FIGURE LEGENDS 
Figure 1. Flow chart showing selection of studies 
Figure 2.  Funnel plot of response 
Figure 3. Forest plot of frequency of diarrhea 
Figure 4. Forest plot of frequency of nausea and vomiting 
Figure 5.  Forest plot of frequency of stomatitis 
Figure 6.  Forest plot of response rate 
Figure 7.  Forest plot of median survival (months) 
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